Misplaced Pages

Mizoribine: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 02:11, 15 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation← Previous edit Latest revision as of 15:26, 9 December 2024 edit undoCitation bot (talk | contribs)Bots5,418,749 edits Added doi. | Use this bot. Report bugs. | Suggested by Dominic3203 | Linked from User:Marbletan/sandbox | #UCB_webform_linked 75/2664 
(19 intermediate revisions by 14 users not shown)
Line 1: Line 1:
{{Short description|Immunosuppressive drug}}
{{drugbox
{{Drugbox
⚫ | verifiedrevid = 444901837
⚫ | IUPAC_name = 5-hydroxy-1-β-<small>D</small>-ribofuranosyl-1''H''-imidazole-4-carboxamide
⚫ | image = Mizoribine.png
<!--Clinical data-->
| tradename =
| Drugs.com = {{drugs.com|international|mizoribine}}
⚫ | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫ | pregnancy_US = <!-- A / B / C / D / X -->
⚫ | pregnancy_category =
⚫ | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫ | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫ | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫ | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫ | legal_status = Rx-only
⚫ | routes_of_administration = Oral
<!--Pharmacokinetic data-->
⚫ | bioavailability =
⚫ | protein_bound =
⚫ | metabolism =
⚫ | elimination_half-life =
⚫ | excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
⚫ | CAS_number = 50924-49-7
⚫ | ATC_prefix = none
⚫ | ATC_suffix =
⚫ | ATC_supplemental =
⚫ | PubChem = 104762
⚫ | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫ | DrugBank =
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4JR41A10VP | UNII = 4JR41A10VP
⚫ | verifiedrevid = 443489181
⚫ | IUPAC_name = 5-hydroxy-1-β-<small>D</small>-ribofuranosyl-1''H''-imidazole-4-carboxamide
⚫ |synonyms = <small>1--5-hydroxyimidazole-4-carboxamide</small>
⚫ | image = Mizoribine.png
⚫ | CAS_number = 50924-49-7
| CAS_supplemental =
⚫ | ATC_prefix = none
⚫ | ATC_suffix =
⚫ | ATC_supplemental =
⚫ | PubChem = 104762
⚫ | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
⚫ | DrugBank =
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01392 | KEGG = D01392
| ChemSpiderID = 94571
⚫ | chemical_formula =
<!--Chemical data-->
⚫ | C=9 | H=13 | N=3 | O=6
⚫ | chemical_formula =
| molecular_weight = 259.21 g/mol
⚫ | C=9 | H=13 | N=3 | O=6
| smiles = C1=NC(=C(N1C2C(C(C(O2)CO)O)O)O)C(=O)N | smiles = C1=NC(=C(N12(((O2)CO)O)O)O)C(=O)N
⚫ | bioavailability =
| StdInChI = 1S/C9H13N3O6/c10-7(16)4-8(17)12(2-11-4)9-6(15)5(14)3(1-13)18-9/h2-3,5-6,9,13-15,17H,1H2,(H2,10,16)/t3-,5-,6-,9-/m1/s1
⚫ | protein_bound =
| StdInChIKey = HZQDCMWJEBCWBR-UUOKFMHZSA-N
⚫ | metabolism =
⚫ | synonyms = <small>1--5-hydroxyimidazole-4-carboxamide</small>
⚫ | elimination_half-life =
⚫ | excretion =
⚫ | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫ | pregnancy_US = <!-- A / B / C / D / X -->
⚫ | pregnancy_category=
⚫ | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
⚫ | legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫ | legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
⚫ | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫ | legal_status = Rx-only
⚫ | routes_of_administration = Oral
}} }}


'''Mizoribine''' (], trade name '''Bredinin''') is an ]. The compound was first observed in Tokyo, ], in 1971.<ref>{{cite journal|title=Mizoribine and Mycophenolate Mofetil|journal=Current Medicinal Chemistry|date=1999|publisher=Bentham Science|pages=575–597|author=Hiroaki Ishikawa|pmid=10390602}}</ref> It is a natural product, first isolated from the mould '']''. '''Mizoribine''' (], trade name '''Bredinin''') is an ]. The compound was first observed in Tokyo, ], in 1971.<ref>{{cite journal | vauthors = Ishikawa H | title = Mizoribine and mycophenolate mofetil | journal = Current Medicinal Chemistry | volume = 6 | issue = 7 | pages = 575–97 | date = July 1999 | pmid = 10390602 | publisher = Bentham Science | doi = 10.2174/092986730607220401123549 }}</ref> First isolated from the fungus '']''. Mizoribine (MZB) is an imidazole nucleoside that has been used in renal transplantation, and in steroid-resistant nephrotic syndrome, IgA nephropathy, lupus, as well as for adults with rheumatoid arthritis, lupus nephritis and other rheumatic diseases. MZB exerts its activity through selective inhibition of inosine monophosphate dehydrogenase and guanosine monophosphate synthetase, resulting in the complete inhibition of guanine nucleotide synthesis without incorporation into nucleotides. It arrests DNA synthesis in the S phase of cellular division. Thus, MZB has less toxicity than azathioprine, another immunosuppressant used for some of the same diseases.


==References== == References ==
{{reflist}} {{reflist}}
{{-}} {{-}}
{{Immunosuppressants}} {{Immunosuppressants}}



] ]



{{antineoplastic-drug-stub}} {{antineoplastic-drug-stub}}

Mizoribine (MZB) is an imidazole nucleoside that has been used in renal transplantation, and in steroid-resistant nephrotic syndrome, IgA nephropathy, lupus, as well as for adults with rheumatoid arthritis, lupus nephritis and other rheumatic diseases. MZB exerts its activity through selective inhibition of inosine monophosphate synthetase and guanosine monophosphate synthetase, resulting in the complete inhibition of guanine nucleotide synthesis without incorporation into nucleotides. It arrests DNA synthesis in the S phase of cellular division. Thus, MZB has less toxicity than azathioprine, another immunosuppressant used for some of the same diseases.